Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 40

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 40
---
 with the materials and services that we use to develop and, if appropriate in the future, manufacture our product candidates
or approved products, we may, at times, share trade secrets and intellectual property with such third parties. We seek to protect our
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research
agreements, consulting agreements, or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning
research or disclosing information. These agreements typically limit the rights of the third parties to use or disclose our confidential
information, such as trade secrets and intellectual property. Despite the contractual provisions employed when working with third parties,
the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors,
are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our
position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized
use or disclosure would impair our competitive position and may have a material adverse effect on our business. In addition, certain of
our officers are also engaged by third parties, including our Chief Financial Officer, which provides his services to us through a third
party service firm. See “Management—Engagement Agreements with Executive Officers” for additional information.

Despite our efforts to protect
our trade secrets and knowhow, our competitors may discover our trade secrets, either through breach of these agreements, independent
development or publication of information including our trade secrets by third parties. A competitor’s discovery of our trade secrets
and knowhow would impair our competitive position and have an adverse impact on our business, financial condition, results of operations
and prospects.

<div align='center'>28</div>

Risks Related to Our Intellectual Property

If we are unable to obtain significant patent protection for our products, or if our patents and other intellectual property rights do not adequately protect our products, we may be unable to gain significant market share and be unable to operate our business profitably.

We will rely on patents, trade
secrets, copyrights, know-how, trademarks, license agreements and contractual provisions to establish our intellectual property rights
and protect our products. These legal means, however, afford only limited protection and may not completely protect our rights.

As of February 10, 2025,
our exclusively owned patent portfolio includes thirty-four (34) issued patents, of which eight (8) are U.S. patents